ENOVA is a science and technology “Network on Vaccine Adjuvants”, funded by COST through the EU Framework Programme Horizon 2020. ENOVA is coordinated by the Vaccine Formulation Institute (UK) and brings together European experts and stakeholders working in different areas of adjuvant and vaccine R&D, including both prophylactic and therapeutic applications as well as human and veterinary vaccines. ENOVA’s members include industry, academic, and government institutions. The ultimate goals of the network are to facilitate communication and the exchange of information among its membership, to ensure that new discoveries are widely disseminated so that their potential can be of optimal benefit, to promote the best use of existing adjuvant technologies, and to encourage and support the development of novel adjuvants.
Review article on adjuvants
Sep. 4, 2020 9:17 AM
ENOVA partners publish review article on the use of adjuvants to boost therapeutic vaccines
WHO publish list of COVID-19 vaccine candidates
June 2, 2020 1:20 PM
WHO today published a " draft landscape of COVID-19 candidate vaccines". A total of 133 vaccines (10 are in clinical trials) covering various platforms (inactivated virus, recombinant virus and proteins, VLPs, DNA/RNA vaccines) are listed. Adjuvants like Alum, Matrix M, Advax TM , CPG1018 and others are included as immune stimulants in the race for this vaccine.
COST COVID-19 information
Mar. 29, 2020 1:03 PM
Information relating to COVID-19 pandemic from COST can be found here
Feb. 28, 2020 10:42 PM
Reports of ENOVA short term missions are now available on our website